City of Hope opens ambulatory cancer center in Irvine as part of $1B expansion

City of Hope launches AI tool to reduce burden of cancer care

City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials, and empower breakthrough research.

June 27, 2025

Vol.51 No.25

From “undruggable” target to clinical potential: The journey of AOH1996

When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

City of Hope has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the U.S. Department of Health and Human Services. The grant will help City of Hope create a biomap of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer.

June 20, 2025

Vol.51 No.24

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

City of Hope researchers presented compelling real-world evidence and novel combination therapies at the 2025 ASCO Annual Meeting, with findings that could reshape treatment approaches for breast, colorectal, renal, and prostate cancers.

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter